Form 4: CRISPR Therapeutics CEO Samarth Kulkarni Acquires Stock Options and Restricted Stock Units
SEC Form 4 Filing
CEO of CRISPR Therapeutics, Samarth Kulkarni, reports acquisition of stock options and restricted stock units.
Summary
- Samarth Kulkarni, CEO of CRISPR Therapeutics, filed a Form 4 disclosing changes in beneficial ownership.
- On March 20, 2024, Kulkarni was granted stock options for 105,000 common shares at an exercise price of $72.94.
- These options vest in 48 equal monthly installments starting April 20, 2024.
- Kulkarni also received 78,750 restricted stock units (RSUs) on March 20, 2024.
- These RSUs vest in four equal installments annually on March 20, starting in 2025 and ending in 2028.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management and shareholder interests.
Positives
- The grant of stock options and RSUs aligns the CEO's interests with those of the shareholders.
- The vesting schedules incentivize long-term performance and commitment from the CEO.
Industry Context
Stock options and RSUs are common forms of executive compensation in the biotechnology industry, aligning management incentives with shareholder value creation.
Comparison to Industry Standards
- Executive compensation packages, including stock options and RSUs, are standard practice in the biotech industry to attract and retain top talent.
- Companies like Vertex Pharmaceuticals and BioMarin Pharmaceutical also utilize similar equity-based compensation strategies for their executives.
- The vesting schedules are typical, designed to incentivize long-term commitment and performance.
Stakeholder Impact
- Shareholders may view the equity grants as a positive sign, aligning the CEO's interests with the company's long-term success.
- Employees may see the CEO's compensation as a reflection of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/20/2024 | Date of earliest transaction: Grant date of stock options and restricted stock units. |
| 03/20/2024 | Stock option grant date. |
| 04/20/2024 | First vesting date for stock options. |
| 03/20/2025 | First vesting date for restricted stock units (one quarter). |
| 03/20/2026 | Second vesting date for restricted stock units (one quarter). |
| 03/20/2027 | Third vesting date for restricted stock units (one quarter). |
| 03/20/2028 | Final vesting date for restricted stock units (one quarter). |
| 03/20/2034 | Expiration date for stock options. |
| 03/22/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.